MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The company has appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from development to market entry.
MindBio’s technology analyzes voice patterns to detect intoxication or impairment without requiring biological testing, positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries. Chile’s mining sector, employing more than 200,000 workers, represents an early target market. The company is preparing to deploy the platform in industrial environments beginning in 2026.
The appointment of Felipe Leyton, a specialist in drug policy, underscores MindBio’s strategic focus on the Chilean mining industry, where workplace safety regulations are stringent and the need for non-invasive impairment detection is high. Leyton’s expertise is expected to facilitate partnerships with mining companies and regulatory bodies.
To support these commercialization activities, MindBio recently closed an upsized non-brokered private placement of up to $1.5 million. The funds will be used to advance the platform’s development and market entry. The company believes that its voice-based AI solution offers a cost-effective and scalable alternative to traditional drug and alcohol testing methods, such as saliva or breathalyzer tests, which can be intrusive and time-consuming.
The mining industry in South America, particularly in Chile, has been seeking innovative safety technologies to reduce accidents and improve compliance. MindBio’s platform could address this need by providing real-time, continuous monitoring of workers’ impairment levels without disrupting operations. The company plans to pilot the technology with select partners before full commercial launch.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection. The company’s technology is designed to enhance safety in industrial environments by enabling proactive impairment screening. For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
